论文部分内容阅读
目的结合在早期随访影像中肿瘤大小和密度衰减的同步变化,对应用舒尼替尼治疗转移性肾细胞癌病人的不同临床结果分别进行修订的Choi、实体瘤疗效评价标准(RECIST)1.1及原始的Choi 3种标准比较。材料与方法 本
OBJECTIVE: To evaluate the different clinical outcomes of patients receiving sunitinib in the treatment of metastatic renal cell carcinoma based on the simultaneous changes of tumor size and density attenuation in early follow-up images, respectively. The revised Choi, RECIST 1.1 and original Choi 3 kinds of standard comparison. Materials and methods of this